Evidence map›Paper›PMID 32628124›Full record

ArticleJournal of medical Internet research2020

A Precision Medicine Tool for Patients With Multiple Sclerosis (the Open MS BioScreen): Human-Centered Design and Development.

Erica Schleimer, Jennifer Pearce, Andrew Barnecut, William Rowles, Antoine Lizee, Arno Klein, Valerie J Block, Adam Santaniello, Adam Renschen, Refujia Gomez and 5 more

Abstract read
In one paragraph

Article in Journal of medical Internet research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Digital Twins for Multiple Sclerosis.Frontiers in immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Erica SchleimerDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0001-5040-6306
Jennifer PearcePlain Language Health, San Francisco, CA, United States.ORCID 0000-0001-6766-6323
Andrew BarnecutDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0003-1003-272X
William RowlesDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-5613-0483
Antoine LizeeDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-1073-3190
Arno KleinChild Mind Institute, New York, NY, United States.ORCID 0000-0002-0707-2889
Valerie J BlockDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0001-6199-5484
Adam SantanielloDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-9816-5932
Adam RenschenDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-8042-6823
Refujia GomezDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0003-0730-8019
Anisha KeshavanDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0003-3554-043X
Jeffrey M GelfandDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-5121-3319
Roland G HenryDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-8232-7562
Stephen L HauserDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-4932-4001
Riley BoveDepartment of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States.ORCID 0000-0002-2034-8800

Funding

The Role of B cells in the Origin and Progression of Multiple SclerosisR35NS111644 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEPHEN L HAUSER · 2019 to 2026
$9.1M
NINDS NIH HHS R35 NS111644
6 · The paper itself

Abstract

backgroundPatients with multiple sclerosis (MS) face several challenges in accessing clinical tools to help them monitor, understand, and make meaningful decisions about their disease course. The University of California San Francisco MS BioScreen is a web-based precision medicine tool initially designed to be clinician facing. We aimed to design a second, openly available tool, Open MS BioScreen, that would be accessible, understandable, and actionable by people with MS.

objectiveThis study aimed to describe the human-centered design and development approach (inspiration, ideation, and implementation) for creating the Open MS BioScreen platform.

methodsWe planned an iterative and cyclical development process that included stakeholder engagement and iterative feedback from users. Stakeholders included patients with MS along with their caregivers and family members, MS experts, generalist clinicians, industry representatives, and advocacy experts. Users consisted of anyone who wants to track MS measurements over time and access openly available tools for people with MS. Phase I (inspiration) consisted of empathizing with users and defining the problem. We sought to understand the main challenges faced by patients and clinicians and what they would want to see in a web-based app. In phase II (ideation), our multidisciplinary team discussed approaches to capture, display, and make sense of user data. Then, we prototyped a series of mock-ups to solicit feedback from clinicians and people with MS. In phase III (implementation), we incorporated all concepts to test and iterate a minimally viable product. We then gathered feedback through an agile development process. The design and development were cyclical-many times throughout the process, we went back to the drawing board.

resultsThis human-centered approach generated an openly available, web-based app through which patients with MS, their clinicians, and their caregivers can access the site and create an account. Users can enter information about their MS (basic level as well as more advanced concepts), visualize their data longitudinally, access a series of algorithms designed to empower them to make decisions about their treatments, and enter data from wearable devices to encourage realistic goal setting about their ambulatory activity. Agile development will allow us to continue to incorporate precision medicine tools, as these are validated in the clinical research arena.

conclusionsAfter engaging intended users into the iterative human-centered design of the Open MS BioScreen, we will now monitor the adaptation and dissemination of the tool as we expand its functionality and reach. The insights generated from this approach can be applied to the development of a number of self-tracking, self-management, and user engagement tools for patients with chronic conditions.

Indexed as

AlgorithmsHumansMultiple SclerosisPrecision Medicinehuman-centered designhuman factorsmobile phoneparticipatory medicinepersonal health recordvisualization in eHealth

Identifiers

PMID32628124
PMCPMC7381029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.